KRAS gene amplification in colorectal cancer and impact on response to EGFR‐targeted therapy

KRAS mutations are the most common oncogenic event in colorectal cancer (CRC) progression and their occurrence is associated with lack of response to anti epidermal growth factor receptor (EGFR) targeted therapies. Using preclinical models and patients' samples we recently reported that the eme...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	International journal of cancer 2013-09, Vol.133 (5), p.1259-1265
Hauptverfasser:	Valtorta, Emanuele, Misale, Sandra, Sartore‐Bianchi, Andrea, Nagtegaal, Iris D., Paraf, François, Lauricella, Calogero, Dimartino, Valentina, Hobor, Sebastijan, Jacobs, Bart, Ercolani, Cristiana, Lamba, Simona, Scala, Elisa, Veronese, Silvio, Laurent‐Puig, Pierre, Siena, Salvatore, Tejpar, Sabine, Mottolese, Marcella, Punt, Cornelis J.A., Gambacorta, Marcello, Bardelli, Alberto, Nicolantonio, Federica
Format:	Artikel
Sprache:	eng
Schlagworte:	Biological and medical sciences biomarkers Cancer Cell Line, Tumor Cellular Biology cetuximab Colorectal cancer Colorectal Neoplasms - drug therapy Colorectal Neoplasms - genetics EGFR EGFR therapy Epidermal growth factor Gastroenterology. Liver. Pancreas. Abdomen Gene Amplification Humans KRAS KRAS amplification Life Sciences Medical research Medical sciences Multiple tumors. Solid tumors. Tumors in childhood (general aspects) Mutation panitumumab Proto-Oncogene Proteins - genetics Proto-Oncogene Proteins p21(ras) ras Proteins - genetics Receptor, Epidermal Growth Factor - antagonists & inhibitors resistance Retrospective Studies Stomach. Duodenum. Small intestine. Colon. Rectum. Anus Tumors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!